A Phase 4 interventional study of Xyrem in Narcolepsy With Cataplexy and Healthy Controls, sponsored by Centre for Addiction and Mental Health. Completed at 1 site in Canada. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-23.
Sponsored by Centre for Addiction and Mental Health · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Narcolepsy with a site in Canada — 4 open to participants now, 4 under way, 2 of them phase 3. Narcolepsy · Canada.
Among the 24 studies in Narcolepsy with a site in Canada, this one is the 22nd largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2016, is one of 2 in phase 4, and was the 9th registered.
158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.
Browse Narcolepsy studies →4 of the 24 studies in Narcolepsy with a site in Canada are open now. Recruiting first, the newest first:
Harmony Biosciences Management, Inc. · Sites in Canada, United States, Belgium and 4 more countries
Ages 18+
Alkermes, Inc. · Sites in Canada, United States, Australia and 12 more countries
Ages 18–70
Eisai Inc. · Sites in Canada, United States, Belgium and 7 more countries
Ages 18+
Centessa Pharmaceuticals (UK) Limited · Sites in Canada, United States, Italy and 1 more country
Ages 18–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 19 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 78 across 114 interventional studies indexed under Narcolepsy.
Median enrollment 150 across the 23 interventional studies, 24 across the 1 observational. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 10 most frequent:
Centre for Addiction and Mental Health is the lead sponsor of 339 studies on the registry; 51 are open to participants now.
Centre for Addiction and Mental Health has 1 study filed under Narcolepsy — fewer than ten, so there is no comparison to draw.
3 of the studies in Narcolepsy with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07455383Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | 2027-05 |
| NCT07675135Phase 3Harmony Biosciences Management, Inc.A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy | 2027-10 |
| NCT07493265Eisai Inc.A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy | 2027-02-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Narcolepsy with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The overall aim of this investigation is to establish whether an action of Xyrem® on the brain dopamine system in patients with narcolepsy, and in a comparison control group, might explain part of the anti-narcoleptic effect of the drug.
Trial Objective is to establish, using positron emission tomography (PET), in Xyrem®-naïve narcolepsy with cataplexy patients, and in matched controls, whether a single dose of Xyrem® causes changes in striatal binding of 11C-raclopride and 11C-DTBZ that would suggest altered activity of brain dopamine neurones.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients given single dose of Xyrem
Drug: Xyrem
healthy controls given a single dose of Xyrem
Drug: Xyrem
single 3.0 gram dose
Also known as: Sodium Oxybate, gamma-hydroxybutyrate
[C-11]Raclopride BPND at 1 Hour Post Xyrem
BPND (Binding Potential) of \[C-11\]raclopride measures 1 hour after taking a single 3g dose of Xyrem.
Time frame: 1 hour post Xyrem
% Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem
\[C-11\] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy. % change was calculated as follows: (1 hour BPND - baseline BPND)/baseline BPND \*100; Mean % change represents the mean of each participant's individual % change within the group.
Time frame: 1 hour post Xyrem
[C-11]Raclopride BPND at 7 Hours Post Xyrem
BPND (Binding Potential) of \[C-11\]raclopride measures 7 hours after taking a single 3g dose of Xyrem.
Time frame: 7 hours post Xyrem
% Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem
\[C-11\] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy. % change was calculated as follows: (7 hours BPND - baseline BPND)/baseline BPND \*100; Mean % change represents the mean of each participant's individual % change within the group.
Time frame: 7 hours post Xyrem
[C-11]DTBZ BPND at 5 Hours Post Xyrem
Measurement of \[C-11\]DTBZ 5 hours after taking a single dose of 3g Xyrem
Time frame: 5 hours post single Xyrem dose
% Change in PET [C-11] Dihydrotetrabenazine (DTBZ) Binding From Baseline to Five Hours Post Xyrem
\[C-11\] DTBZ is a radioligand that binds to the vesicular monoamine transporter and which is sensitive to dopamine occupancy. % change was calculated as follows: (5 hour BPND - baseline BPND)/baseline BPND \*100; Mean % change represents the mean of each participant's individual % change within the group.
Time frame: 5 hours post single Xyrem dose
Blood Gamma-hydroxybutyrate (GHB) Concentration (AUC)
The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem, as measured by Area Under the Curve.
Time frame: multiple time points from 0 to 7 hours post-Xyrem
Blood Gamma-hydroxybutyrate (GHB) Cmax
The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem as measured by Cmax.
Time frame: multiple time points from 0 to 7 hours post-Xyrem
Duration of Drowsiness
Period of time when the participant was experiencing the sedative action of Xyrem. Data derived from self-report as well as anesthesiologist observation.
Time frame: observed after receiving single dose of Xyrem, up to 9 hours
| Milestone | Narcolepsy With Cataplexy | Healthy Controls |
|---|---|---|
| Started | 2 | 15 |
| Completed | 1 | 10 |
| Not completed | 1 | 5 |
| Withdrew: Due to technical difficulties, the 1 hour post pet scan was not completed at the one hour time point | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 4 |
BPND (Binding Potential) of \[C-11\]raclopride measures 1 hour after taking a single 3g dose of Xyrem.
| BPND (Binding Potential) | Narcolepsy With Cataplexy | Healthy Controls |
|---|---|---|
| Limbic Striatum | 2.94 | 3.01 ± 0.28 |
| Associate Striatum | 3.80 | 3.70 ± 0.33 |
| Sensorimotor Striatum | 3.87 | 4.11 ± 0.49 |
\[C-11\] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy. % change was calculated as follows: (1 hour BPND - baseline BPND)/baseline BPND \*100; Mean % change represents the mean of each participant's individual % change within the group.
| percentage change from baseline | Narcolepsy With Cataplexy | Healthy Controls |
|---|---|---|
| Limbic Stiatum | 13.27 | 6.49 ± 8.60 |
| Associative Striatum | 23.88 | 2.11 ± 8.59 |
| Sensorimotor Striatum | 24.43 | 1.93 ± 8.85 |
BPND (Binding Potential) of \[C-11\]raclopride measures 7 hours after taking a single 3g dose of Xyrem.
| BPND (Binding Potential) | Narcolepsy With Cataplexy | Healthy Controls |
|---|---|---|
| Limbic Striatum | 2.33 | 2.76 ± 0.18 |
| Associate Striatum | 2.83 | 3.62 ± 0.29 |
| Sensorimotor Striatum | 2.75 | 4.06 ± 0.40 |
\[C-11\] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy. % change was calculated as follows: (7 hours BPND - baseline BPND)/baseline BPND \*100; Mean % change represents the mean of each participant's individual % change within the group.
| percentage change from baseline | Narcolepsy With Cataplexy | Healthy Controls |
|---|---|---|
| Limbic Striatum | -10.13 | -2.07 ± 8.24 |
| Associative Striatum | -7.50 | 0.17 ± 7.42 |
| Sensorimotor Striatum | -11.56 | 0.72 ± 7.64 |
Measurement of \[C-11\]DTBZ 5 hours after taking a single dose of 3g Xyrem
| BPND (binding potential) | Narcolepsy With Cataplexy | Healthy Controls |
|---|---|---|
| Limbic Striatum | 1.71 | 1.82 ± 0.24 |
| Associative Striatum | 2.56 | 2.65 ± 0.40 |
| Sensorimotor Striatum | 2.65 | 3.12 ± 0.53 |
\[C-11\] DTBZ is a radioligand that binds to the vesicular monoamine transporter and which is sensitive to dopamine occupancy. % change was calculated as follows: (5 hour BPND - baseline BPND)/baseline BPND \*100; Mean % change represents the mean of each participant's individual % change within the group.
| percentage change from baseline | Narcolepsy With Cataplexy | Healthy Controls |
|---|---|---|
| Limbic Striatum | 2.00 | -1.98 ± 9.20 |
| Associative Striatum | 6.10 | 2.04 ± 11.84 |
| Sensorimotor Striatum | 6.51 | 2.47 ± 12.09 |
The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem, as measured by Area Under the Curve.
| AUC (ug/ml*hr) | Narcolepsy With Cataplexy | Healthy Controls |
|---|---|---|
| Blood Gamma-hydroxybutyrate (GHB) Concentration (AUC) | 187.03 | 178.49 ± 52.12 |
The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem as measured by Cmax.
| mg/ml | Narcolepsy With Cataplexy | Healthy Controls |
|---|---|---|
| Blood Gamma-hydroxybutyrate (GHB) Cmax | 107 | 107.37 ± 32.95 |
Period of time when the participant was experiencing the sedative action of Xyrem. Data derived from self-report as well as anesthesiologist observation.
| minutes | Narcolepsy With Cataplexy | Healthy Controls |
|---|---|---|
| Duration of Drowsiness | 220.20 | 92.4 (10.02 to 285.00) |
Collected over Adverse events will be assessed at each study visit following administration of the first PET radiotracer until the follow-up phone after Xyrem administration (2 visits plus 1 follow-up phone call), an average of 10 days per participant.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Narcolepsy With Cataplexy | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Healthy Controls | 0/15 (0%) | 0/15 (0%) | 4/15 (26.7%) |
| Event | Narcolepsy With Cataplexy | Healthy Controls |
|---|---|---|
| NauseaGeneral disorders | 0/2 | 3/15 |
| EuphoriaGeneral disorders | 0/2 | 1/15 |
| Age, Continuous(years) | Narcolepsy With Cataplexy | Healthy Controls | Total |
|---|---|---|---|
| Mean | 52 | 29.6 ± 8 | 31.6 ± 10 |
| Sex: Female, Male(Participants) | Narcolepsy With Cataplexy | Healthy Controls | Total |
|---|---|---|---|
| Female | 1 | 4 | 5 |
| Male | 0 | 6 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Narcolepsy With Cataplexy | Healthy Controls | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 10 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Narcolepsy With Cataplexy | Healthy Controls | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 6 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 1 | 3 | 4 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Narcolepsy With Cataplexy | Healthy Controls | Total |
|---|---|---|---|
| Canada | 1 | 10 | 11 |
| [C-11]raclopride BPND at Baseline(BPND (Binding Potential)) | Narcolepsy With Cataplexy | Healthy Controls | Total |
|---|---|---|---|
| Limbic Striatum | 2.59 | 2.83 ± 0.19 | 2.80 ± 0.19 |
| Associative Striatum | 3.06 | 3.63 ± 0.32 | 3.58 ± 0.35 |
| Sensorimotor Striatum | 3.11 | 4.04 ± 0.43 | 3.96 ± 0.49 |
| [C-11]DTBZ BPND at Baseline(BPND (Binding Potential)) | Narcolepsy With Cataplexy | Healthy Controls | Total |
|---|---|---|---|
| Limbic Striatum | 1.68 | 1.85 ± 0.19 | 1.84 ± 0.18 |
| Associative Striatum | 2.41 | 2.60 ± 0.26 | 2.58 ± 0.25 |
| Sensorimotor Striatum | 2.49 | 3.05 ± 0.38 | 3.00 ± 0.40 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jan 2016, a primary completion of Jan 2020 and a completion of Jan 2020. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2021, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium Oxybate
Centre for Addiction and Mental Health →